| SPYRE THERAPEUTICS INC. |
| USA |
| Gesundheit |
| US00773J2024 / A3D4LY |
| 3920 (Frankfurt) / SYRE (NASDAQ) |
| FRA:3920, ETR:3920, 3920:GR, NASDAQ:SYRE |
| - |
| https://spyre.com/ |
|
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company developing next-generation antibodies engineered for prolonged activity in the body, formulated for delivery as monotherapies or combination therapies. These innovative antibodies tar..
>Volltext.. |
| 7149.19 Mio. EUR |
| 6643.29 Mio. EUR |
| - |
| -209.55 Mio. EUR |
| -146.33 Mio. EUR |
| -2.04 EUR |
| - |
| 84.28 Mio. EUR |
| -161.19 Mio. EUR |
| 8.71 |
| - |
| 1.39% |
| - |
| - |
| - |
| - |
| SPYRE THERAPEUTICS, SPYRE THERAPEUTIC |
| 06.08.26 |